GLP-1s: Safe Dosing, Nutrition & Impact on Longevity | Rhonda Patrick, Ph.D.
Peter Attia, MD — GLP-1s: Safe Dosing, Nutrition & Impact on Longevity | Rhonda Patrick, Ph.D.
Channel: Peter Attia MD · Our label: Physician educator · Source: youtube.com/watch?v=Rkr4FnVPlkM
What this video covers
I would say 15 to 20% of our patients are on trespathide. Um and unlike five years ago when we started using semiglutide in patients and were just watching muscle fall off these people and and frankly my point of view five years ago was I don’t know about these drugs. I I think you know I think there’s some benefit in some people but I I think there’s a lot of downside. I I today think that virtually anybody can use these drugs safely, but and by safely, I I don’t just mean in the obvious sense of the word.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- I I today think that virtually anybody can use these drugs safely, but and by safely, I I don’t just mean in the obvious sense of the word.
- I mean safely for long-term muscle health as well, right?
- What I’m interested in is, you know, we have these GLP1 receptors like on so many different tissues.
- But the real question is if you take a person who is of normal weight who does not have type two diabetes but maybe has a higher risk for Alzheimer’s disease and you micro dose them.
So they’re they’re looking more metabolically healthy.
- And in one case in particular, it was so confusing that even after all the genetic testing we did, like we simply couldn’t figure out an answer for this.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.